LPPEPTIDE | ARA290 | 10mg*10vials | 10mg*10vials

What is ARA290?

Ara-290 (cibinetide) is an 11–amino acid non-erythropoietic peptide derived from erythropoietin’s helix-B domain. It selectively activates the innate repair receptor (IRR), an EPOR/CD131 heterodimer, to promote anti-inflammatory and tissue-protective effects without stimulating red blood cell production. Clinical trials have demonstrated benefits for diabetic neuropathy and sarcoidosis-related small-fiber neuropathy

Research context

Preclinical research demonstrates that Ara-290 can reprogram a pro-inflammatory, tissue-damaging environment into one favoring healing and regeneration. Additionally, analgesic effects have been observed through immunomodulation and direct inhibition of TRPV1 ion channels activated by capsaicin

Reference literature focus

Ara-290 (cibinetide) binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (βc subunit), which is distinct from the classical erythropoietin receptor. This selective binding triggers anti-apoptotic and anti-inflammatory signaling cascades that protect tissues and promote repair without stimulating erythropoiesis.

LPPeptide handling reference

Suggested daily titration approach reflecting clinical study parameters. Start: 2 mg daily during week 1 to assess tolerance. Target: 4 mg daily from week 2 onward[3]. Frequency: Once per day (subcutaneous). Cycle Length: 4–8 weeks standard; may extend to 16 weeks based on individual assessment. Timing: Any consistent time daily; rotate injection sites.

Preparation

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days and do not freeze the liquid solution. Allow vials to reach room temperature before opening to minimize condensation; protect from light. Discard if discoloration, cloudiness, or particulate matter is obser

Storage

Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2 years; freeze at −20 °C (−4 °F) for extended storage up to 3 years

Safety observations

Observations from preclinical and clinical literature. Neuroprotection: Clinical trials in diabetic neuropathy showed improvements in HbA1c, lipid profiles, and neuropathic pain scores with 4 mg daily dosing. Nerve regeneration: In sarcoidosis-associated small-fiber neuropathy, treatment led to significant increases in corneal nerve fiber density (objective nerve regrowth) and improved symptoms compared to placebo. Tissue protection: Anti-inflammatory and anti-apoptotic effects observed across multiple organ systems in preclinical models. No erythropoietic effects: Unlike full EPO, Ara-290 does not stimulate red blood cell production, avoiding related side effects. Tolerability: Well tolerated in clinical studies; occasional mild injection-site reactions (redness, transient discomfort) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies that may support therapeutic goals. Optimize glycemic control through diet and medication adherence if addressing diabetic neuropathy. Incorporate regular physical activity appropriate to individual capacity to support nerve health and circulation. Prioritize adequate sleep and stress management to support tissue repair processes. Avoid smoking and limit alcohol consumption, both of which can exacerbate neuropathic conditions.

Certificate of Analysis

Each LPPeptide lot should be confirmed against current batch documentation before shipment or study use. This product page keeps ARA290 visible so the SKU can be matched to the active COA.

Direct catalog supply

LPPeptide product pages use our own SKU, package, price, and stock data first. LPPeptide knowledge mapping adds compound education, handling notes, and specification checks while lot-specific editorial content is being prepared.

Lot-specific content

For final release decisions, use the current product record, COA, handling sheet, and research SOP as the highest-priority source for this page.